Table III.
Cost-effectiveness of cast compared to removable brace (£, 2019).
| Cost effectiveness threshold | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Incremental cost (95% CI) |
Incremental QALY (95% CI) |
ICER | Probability* | Probability† | Probability‡ | NMB*, mean (95% CI) | NMB†, mean (95% CI) | NMB‡, mean (95% CI) |
| Base case§ | 46.73 (--9 to 147) | 0.014 (-.005 to 0.033) | 3,318 | 0.81 | 0.84 | 0.88 | 164.52 (-191.10 to 527.21) | 234.93 (-203.03 to 686.02) |
375.76 (-229.72 to 1007.94) |
| Complete case¶ | 289.65 (-133 to 712) | 0.013 (-0.020 to 0.047) | 21,499 | 0.41 | 0.48 | 0.58 | -87.56 (-817.6 to 597.73) |
-20.19 (-880.26 to 818.70) |
114.54 (-1050.34 to 1263.19) |
| Societal perspective§ | 101.42 (-495 to 697) | 0.014 (-0.005 to 0.033) | 7,264 | 0.63 | 0.68 | 0.76 | 108.02 (-622.48 to 836.32) |
177.84 (-614.23 to 951.36 |
317.47 (-580.70 to 1190.58) |
*
At £15,000.
†
At £20,000.
‡
At £25,000.
§
Imputed model: costs and qualtiy of life years (QALYs) adjusted for age, sex, and ankle fracture management; QALYs adjusted for baseline EuroQol five-dimension (EQ-5D).
¶
Attributable costs and QALYs adjusted for age, sex, and ankle fracture management; QALYs adjusted for baseline EQ-5D.
CI, confidence interval; ICER, incremental cost-effectiveness ratio ; NMB, net monetary benefit.